These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
511 related items for PubMed ID: 24210779
1. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Lancet; 2014 Feb 15; 383(9917):622-9. PubMed ID: 24210779 [Abstract] [Full Text] [Related]
2. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL, SYMPLICITY HTN-3 Steering Committee Investigators. Lancet; 2022 Oct 22; 400(10361):1405-1416. PubMed ID: 36130612 [Abstract] [Full Text] [Related]
3. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Böhm M, SPYRAL HTN-OFF MED trial investigators*. Lancet; 2017 Nov 11; 390(10108):2160-2170. PubMed ID: 28859944 [Abstract] [Full Text] [Related]
4. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Dimitriadis K, Choi JW, East C, D'Souza R, Sharp ASP, Ewen S, Walton A, Hopper I, Brar S, McKenna P, Fahy M, Böhm M. Lancet; 2022 Apr 09; 399(10333):1401-1410. PubMed ID: 35390320 [Abstract] [Full Text] [Related]
5. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Lancet; 2009 Apr 11; 373(9671):1275-81. PubMed ID: 19332353 [Abstract] [Full Text] [Related]
6. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP. Eur Heart J; 2014 Jul 11; 35(26):1752-9. PubMed ID: 24898552 [Abstract] [Full Text] [Related]
7. Renal denervation in moderate treatment-resistant hypertension. Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, Spies A, Ukena C, Laufs U, Uder M, Böhm M, Schmieder RE. J Am Coll Cardiol; 2013 Nov 12; 62(20):1880-6. PubMed ID: 23850901 [Abstract] [Full Text] [Related]
8. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN). Fengler K, Rommel KP, Blazek S, Besler C, Hartung P, von Roeder M, Petzold M, Winkler S, Höllriegel R, Desch S, Thiele H, Lurz P. Circulation; 2019 Jan 29; 139(5):590-600. PubMed ID: 30586691 [Abstract] [Full Text] [Related]
9. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Symplicity HTN-2 InvestigatorsBaker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road, Central Melbourne, VIC 8008, Australia. murray.esler@bakeridi.edu.au, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Lancet; 2010 Dec 04; 376(9756):1903-9. PubMed ID: 21093036 [Abstract] [Full Text] [Related]
10. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G, Renal Denervation for Hypertension (DENERHTN) investigators. Lancet; 2015 May 16; 385(9981):1957-65. PubMed ID: 25631070 [Abstract] [Full Text] [Related]
11. Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes. Al Ghorani H, Kulenthiran S, Lauder L, Recktenwald MJM, Dederer J, Kunz M, Götzinger F, Ewen S, Ukena C, Böhm M, Mahfoud F. Clin Res Cardiol; 2024 Oct 16; 113(10):1384-1392. PubMed ID: 38451261 [Abstract] [Full Text] [Related]
12. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Papademetriou V, Tsioufis CP, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Worthley MI, Worthley SG. Hypertension; 2014 Sep 16; 64(3):565-72. PubMed ID: 24935940 [Abstract] [Full Text] [Related]
13. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Kiuchi MG, Maia GL, de Queiroz Carreira MA, Kiuchi T, Chen S, Andrea BR, Graciano ML, Lugon JR. Eur Heart J; 2013 Jul 16; 34(28):2114-21. PubMed ID: 23786861 [Abstract] [Full Text] [Related]
14. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, SPYRAL HTN-ON MED Trial Investigators. Lancet; 2018 Jun 09; 391(10137):2346-2355. PubMed ID: 29803589 [Abstract] [Full Text] [Related]
15. Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients With Resistant Hypertension. Sesa-Ashton G, Nolde JM, Muente I, Carnagarin R, Lee R, Macefield VG, Dawood T, Sata Y, Lambert EA, Lambert GW, Walton A, Kiuchi MG, Esler MD, Schlaich MP. Hypertension; 2023 Apr 09; 80(4):811-819. PubMed ID: 36762561 [Abstract] [Full Text] [Related]
16. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Høieggen A. Hypertension; 2014 May 09; 63(5):991-9. PubMed ID: 24591332 [Abstract] [Full Text] [Related]
17. Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. Ott C, Mahfoud F, Schmid A, Toennes SW, Ewen S, Ditting T, Veelken R, Ukena C, Uder M, Böhm M, Schmieder RE. J Hypertens; 2015 Jun 09; 33(6):1261-6. PubMed ID: 25923731 [Abstract] [Full Text] [Related]
18. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Eur Heart J; 2013 Jul 09; 34(28):2132-40. PubMed ID: 23782649 [Abstract] [Full Text] [Related]
19. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. Sievert H, Schofer J, Ormiston J, Hoppe UC, Meredith IT, Walters DL, Azizi M, Diaz-Cartelle J, Cohen-Mazor M. EuroIntervention; 2015 Feb 09; 10(10):1213-20. PubMed ID: 25452197 [Abstract] [Full Text] [Related]
20. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators. J Am Coll Cardiol; 2015 Apr 07; 65(13):1314-1321. PubMed ID: 25835443 [Abstract] [Full Text] [Related] Page: [Next] [New Search]